Literature DB >> 26375926

Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice.

Xian Wu1, Gang Pang1, Yong-Mei Zhang2, Guangwu Li1, Shengchun Xu1, Liuyi Dong1, Robert W Stackman3, Gongliang Zhang1,3.   

Abstract

Abuse and dependence to heroin has evolved into a global epidemic as a significant clinical and societal problem with devastating consequences. Repeated exposure to heroin can induce long-lasting behavioral sensitization and withdrawal. Pharmacological activation of 5-HT2C receptors (5-HT2CRs) suppresses psychostimulant-induced drug-seeking and behavioral sensitization. The present study examined the effect of a selective 5-HT2CR agonist lorcaserin on behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice. Male mice received heroin (1.0 mg/kg, s.c.) twice a day for 3 days and then drug treatment was suspended for 5 days. On day 9, a challenge dose of heroin (1.0 mg/kg) was administered to examine the expression of behavioral sensitization. Lorcaserin administered during the development, withdrawal or expression stage suppressed heroin-induced behavioral sensitization on day 9. Another cohort of mice received increasing doses of heroin over a 4.5-day period. Lorcaserin, or the positive control clonidine (an α2-adrenoceptor agonist) suppressed naloxone-precipitated withdrawal symptoms in heroin-treated mice. These findings suggest that activation of 5-HT2CRs suppresses behavioral sensitization and withdrawal in heroin-treated mice. Thus, pharmacological activation of 5-HT2CRs may represent a new avenue for the treatment of heroin addiction.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  5-HT(2C) receptor; Behavioral sensitization; Heroin; Serotonin; Withdrawal

Mesh:

Substances:

Year:  2015        PMID: 26375926      PMCID: PMC4631619          DOI: 10.1016/j.neulet.2015.09.013

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  24 in total

Review 1.  Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction.

Authors:  M J Christie
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

2.  Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.

Authors:  Theodore J Cicero; James A Inciardi; Alvaro Muñoz
Journal:  J Pain       Date:  2005-10       Impact factor: 5.820

3.  Differential effects of serotonin (5-HT)2 receptor-targeting ligands on locomotor responses to nicotine-repeated treatment.

Authors:  Magdalena Zaniewska; Andrew C McCreary; Karolina Wydra; Małgorzata Filip
Journal:  Synapse       Date:  2010-07       Impact factor: 2.562

4.  Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats.

Authors:  K Eberle-Wang; Z Mikeladze; K Uryu; M F Chesselet
Journal:  J Comp Neurol       Date:  1997-07-28       Impact factor: 3.215

5.  Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.

Authors:  C E Spivak; C L Beglan; B K Seidleck; L D Hirshbein; C J Blaschak; G R Uhl; C K Surratt
Journal:  Mol Pharmacol       Date:  1997-12       Impact factor: 4.436

6.  Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.

Authors:  A Gobert; J M Rivet; F Lejeune; A Newman-Tancredi; A Adhumeau-Auclair; J P Nicolas; L Cistarelli; C Melon; M J Millan
Journal:  Synapse       Date:  2000-06-01       Impact factor: 2.562

7.  Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal.

Authors:  Magdalena Zaniewska; Andrew C McCreary; Karolina Wydra; Małgorzata Filip
Journal:  Neuropharmacology       Date:  2010-02-11       Impact factor: 5.250

8.  Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.

Authors:  Brian M Smith; Jeffrey M Smith; James H Tsai; Jeffrey A Schultz; Charles A Gilson; Scott A Estrada; Rita R Chen; Douglas M Park; Emily B Prieto; Charlemagne S Gallardo; Dipanjan Sengupta; Peter I Dosa; Jon A Covel; Albert Ren; Robert R Webb; Nigel R A Beeley; Michael Martin; Michael Morgan; Stephen Espitia; Hazel R Saldana; Christina Bjenning; Kevin T Whelan; Andrew J Grottick; Frederique Menzaghi; William J Thomsen
Journal:  J Med Chem       Date:  2007-12-21       Impact factor: 7.446

9.  Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine: comparison with N-methyl-D-aspartate antagonists.

Authors:  M E Wolf; S L Dahlin; X T Hu; C J Xue; K White
Journal:  Neuroscience       Date:  1995-11       Impact factor: 3.590

10.  Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo.

Authors:  M J Millan; A Dekeyne; A Gobert
Journal:  Neuropharmacology       Date:  1998-07       Impact factor: 5.250

View more
  17 in total

Review 1.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

2.  Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.

Authors:  Laura Brandt; Jermaine D Jones; Suky Martinez; Jeanne M Manubay; Shanthi Mogali; Tatiana Ramey; Frances R Levin; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2020-01-17       Impact factor: 4.492

3.  Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys.

Authors:  E Andrew Townsend; S Stevens Negus; Justin L Poklis; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2020-01-17       Impact factor: 4.492

4.  Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys.

Authors:  Stephen J Kohut; Jack Bergman
Journal:  Eur J Pharmacol       Date:  2018-09-27       Impact factor: 4.432

5.  Innovative Therapeutic Intervention For Opioid Use Disorder.

Authors:  F Gerard Moeller; Kathryn A Cunningham
Journal:  Neuropsychopharmacology       Date:  2018-01       Impact factor: 7.853

6.  Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats.

Authors:  Harshini Neelakantan; Erica D Holliday; Robert G Fox; Sonja J Stutz; Sandra D Comer; Margaret Haney; Noelle C Anastasio; F Gerard Moeller; Kathryn A Cunningham
Journal:  ACS Chem Neurosci       Date:  2017-02-13       Impact factor: 4.418

Review 7.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

8.  A genetic reduction in the serotonin transporter differentially influences MDMA and heroin induced behaviours.

Authors:  Bridget W Brox; Bart A Ellenbroek
Journal:  Psychopharmacology (Berl)       Date:  2018-03-21       Impact factor: 4.530

9.  Choice between delayed food and immediate opioids in rats: treatment effects and individual differences.

Authors:  Leigh V Panlilio; Maria E Secci; Charles W Schindler; Charles W Bradberry
Journal:  Psychopharmacology (Berl)       Date:  2017-09-04       Impact factor: 4.530

Review 10.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.